LUCENTIS (ranibizumab injection) – an biologic monoclonal antibody commonly used to treat certain eye conditions. Ranibizumab binds to the receptor binding site of active forms of VEGF-A, including the biologically active, cleaved form of this molecule, VEGF110. VEGF-A has been shown to cause neovascularization and leakage in models of ocular angiogenesis and vascular occlusion and […]
LOVENOX (enoxaparin) – a low molecular weight heparin commonly used in clinical settings where anticoagulation is needed. Low molecular weight heparins exert their clinical effect through the antithrombotic properties of heparins. FDA approved uses: Lovenox is indicated for: Prophylaxis of deep vein thrombosis (DVT) in abdominal surgery, hip replacement surgery, knee replacement surgery, or medical […]
AVONEX (interferon beta 1-a) – an interferon beta product commonly used to treat patients with relapsing forms of multiple sclerosis (MS). The mechanism by which Avonex exerts its effects in the treatment of MS is unknown. FDA approved uses: Avonex is indicated for the treatment of patients with relapsing forms of multiple sclerosis to slow […]
SUBOXONE (buprenorphine and naloxone) – a sublingual tablet containing buprenorphine and naloxone commonly used to treat opiate dependence. Buprenorphine is a partial agonist at the mu-opioid receptor and an antagonist at the kappa-opioid receptor. Naloxone is a potent antagonist at mu-opioid receptors and produces opioid withdrawal signs and symptoms in individuals physically dependent on full […]